

| |
|--------------------------------------|
| PATENT ASSIGNMENT COVER SHEET |
|--------------------------------------|

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT4615749

| | |
|---|------------------------------|
| SUBMISSION TYPE: | NEW ASSIGNMENT |
| NATURE OF CONVEYANCE: | ASSIGNMENT |
| CONVEYING PARTY DATA | |
| Name | Execution Date |
| HERRIOT TABUTEAU | 03/13/2017 |
| RECEIVING PARTY DATA | |
| Name: | ANTECIP BIOVENTURES II LLC |
| Street Address: | 630 FIFTH AVENUE, SUITE 2000 |
| City: | NEW YORK |
| State/Country: | NEW YORK |
| Postal Code: | 10111 |
| PROPERTY NUMBERS Total: 1 | |
| Property Type | Number |
| Application Number: | 15599319 |
| CORRESPONDENCE DATA | |
| Fax Number: | (949)453-1104 |
| <i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i> | |
| Phone: | 949-202-1900 |
| Email: | Docket@mabr.com |
| Correspondent Name: | BRENT A. JOHNSON |
| Address Line 1: | MASCHOFF BRENNAN |
| Address Line 2: | 20 PACIFICA, SUITE 1130 |
| Address Line 4: | IRVINE, CALIFORNIA 92618 |
| ATTORNEY DOCKET NUMBER: | A3226.10005US16 |
| NAME OF SUBMITTER: | MARIA NADAL |
| SIGNATURE: | /Maria Nadal/ |
| DATE SIGNED: | 09/27/2017 |
| Total Attachments: 9 | |
| source=EXECUTED ASSIGNMENT 3-2017#page1.tif | |
| source=EXECUTED ASSIGNMENT 3-2017#page2.tif | |
| source=EXECUTED ASSIGNMENT 3-2017#page3.tif | |
| source=EXECUTED ASSIGNMENT 3-2017#page4.tif | |
| source=EXECUTED ASSIGNMENT 3-2017#page5.tif | |

source=EXECUTED ASSIGNMENT 3-2017#page6.tif

source=EXECUTED ASSIGNMENT 3-2017#page7.tif

source=EXECUTED ASSIGNMENT 3-2017#page8.tif

source=EXECUTED ASSIGNMENT 3-2017#page9.tif

ASSIGNMENT

THIS ASSIGNMENT is made by **Herriot Tabuteau** (hereafter, together with any successors, legal representatives, or assigns thereof, "ASSIGNOR") to **Antecip Bioventures II LLC**, a legal entity having its principal place of business at 630 Fifth Avenue, Suite 2000, New York, New York 10111 (hereafter, together with any successors, legal representatives, or assigns thereof, "ASSIGNEE").

WHEREAS, ASSIGNOR has invented and owns rights in, to and under new and useful inventions for which an application(s) for or Letters Patent has been filed as indicated on Exhibit A (hereafter "Inventions");

WHEREAS, ASSIGNOR believes himself to be the original and true inventor of the Inventions;

WHEREAS, ASSIGNEE desires to acquire the Inventions and improvements thereto;

AND WHEREAS, ASSIGNOR and ASSIGNEE desire to have a recordable instrument assigning ASSIGNEE as owners of the entire right, title and interest in, to, and under the Inventions and improvements thereto owned by ASSIGNOR;

NOW THEREFORE, for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, ASSIGNOR does hereby sell, assign, transfer, convey, endorse, and hereby set over unto ASSIGNEE the full and exclusive right, title and interest in, to and under the Inventions to be held and enjoyed by ASSIGNEE, as fully and entirely as the same would have been held and enjoyed by ASSIGNOR had this assignment and sale not been made including the full and exclusive right, title and interest in, to and under 1) any patent application, or any other legal instrument equivalent thereof, including, without limitation, continuation, division, continuation-in-part, substitute, reexamination, renewal, inventor's certificate, and utility model, which has been or may be submitted therefor and thereon anywhere in the World, such term defined herein as including the United States of America, its territorial possessions, and any and all foreign countries under national laws or under the provisions of the International Convention for the Protection of Industrial Property, the Patent Cooperation Treaty, or any other international treaty equivalent thereof; 2) any Letters Patent, or any other legal instrument equivalent thereof, which has been or may be granted therefor and thereon, in the World, for the full term or terms for which the same may be granted; 3) any reissue, extension, or any other legal instrument equivalent thereof, on any patent application or Letters Patent which has been or may be granted therefor and thereon in the World; and 4) any right to claim priority to a filing date, or any other legal equivalent thereof, which has been or may be claimed by any patent application or Letters Patent therefor and thereon in the World.

ASSIGNOR hereby covenants and agrees to perform any lawful action when deemed essential by and to ASSIGNEE's full enjoyment, protection, enforcement and title in, to and under the Inventions and rights hereby transferred, including, but not limited to, promptly communicating and providing any and all known and accessible facts, data or any other pertinent information; promptly executing and delivering any and all papers, documents, forms, declarations, oaths, affidavits or any other legal instrument; promptly assisting and participating in any and all depositions, hearings, proceedings, trials, appeals, or any other legal procedure; promptly testifying under oath in any and all interference, post grant review, litigation or any other


administrative or judicial proceeding; and promptly completing any and all actions necessary or desirable to carry out any and all purposes thereof, relating to any and all proceedings in connection with the submission, procurement, issuance, maintenance, enforcement or defense of the inventions and rights hereby transferred.

A Notary Public or other officer completing this certificate verifies only the identity of the individual who signed the document to which this certificate is attached and not the truthfulness accuracy or validity of that document.

IN TESTIMONY WHEREOF, I hereunder set my hand this 13th day of March, 2017.

ASSIGNOR


Herriot Tabuteau



Signature

State of CALIFORNIA)
)
County of ORANGE) ss.:

On this 13 day of March, 2017, before me, Maria Emilia Nadal, personally appeared **Herriot Tabuteau**, who proved to me on the basis of satisfactory evidence to be the person whose name is subscribed to the within instrument and acknowledged to me that he executed the same in his authorized capacity and that by his signature on the instrument the person, or the entity upon behalf of which the person acted, executed the instrument.

Witness my hand and official seal.


Notary Public



A Notary Public or other officer completing this certificate verifies only the identity of the individual who signed the document to which this certificate is attached and not the truthfulness accuracy or validity of that document.

ACKNOWLEDGED AND CONFIRMED, I hereunder set my hand this 13th day of March, 2017, as a duly authorized representative of ASSIGNEE.

ASSIGNEE


Name: Herriot Tabuteau, MD
Title: Managing Member

State of CALIFORNIA)
)
County of ORANGE) ss.:

On this 13 day of March, 2017, before me, Maria Emilia Nadal, personally appeared **Herriot Tabuteau** who proved to me on the basis of satisfactory evidence to be the person whose name is subscribed to the within instrument and acknowledged to me that he executed the same in his authorized capacity and that by his signature on the instrument the person, or the entity upon behalf of which the person acted, executed the instrument.

Witness my hand and official seal. Maria E. Nadal
Notary Public




EXHIBIT A**Patent Rights: Patents and Patent Applications**

| Title | Application/Serial No. | Filing Date |
|--|-------------------------------|--------------------|
| COMPOSITIONS AND METHODS FOR INCREASING THE METABOLIC LIFETIME OF DEXTROMETHORPHAN AND RELATED PHARMACODYNAMIC EFFECTS | 15/182/253 | 6/14/2016 |
| COMPOSITIONS COMPRISING RANK/RANKL ANTAGONISTS AND RELATED COMPOUNDS FOR TREATING PAIN | 15/182,378 | 6/14/2016 |
| COMPOSITIONS FOR ORAL ADMINISTRATION OF ZOLEDRONIC ACID OR RELATED COMPOUNDS FOR TREATING COMPLEX REGIONAL PAIN SYNDROME | 15/188,725 | 6/21/2016 |
| COMPOSITIONS AND METHODS FOR INCREASING THE METABOLIC LIFETIME OF DEXTROMETHORPHAN AND RELATED PHARMACODYNAMIC EFFECTS | 15/206,057 | 7/8/2016 |
| THERAPEUTIC COMPOSITIONS COMPRISING IMIDAZOLE AND IMIDAZOLIUM COMPOUNDS | 15/211,827 | 7/15/2016 |
| BUPROPION AS A MODULATOR OF DRUG ACTIVITY | 15/213,283 | 7/18/2016 |
| BUPROPION AS A MODULATOR OF DRUG ACTIVITY | 15/216,545 | 7/21/2016 |
| OSTEOCLAST INHIBITORS FOR JOINT CONDITIONS | 15/217,752 | 7/22/2016 |
| OSTEOCLAST INHIBITORS FOR BONE MARROW LESIONS | 15/217,773 | 7/22/2016 |
| COMPOSITIONS FOR ORAL ADMINISTRATION OF ZOLEDRONIC ACID OR RELATED COMPOUNDS FOR TREATING LOW BACK PAIN | 15/223,548 | 7/29/2016 |

| | | |
|--|------------|-----------|
| BUPROPION AS A MODULATOR OF DRUG ACTIVITY | 15/224,233 | 7/29/2016 |
| METHODS FOR THE SAFE ADMINISTRATION OF IMIDAZOLE OR IMIDAZOLIUM COMPOUNDS | 15/223,487 | 7/29/2016 |
| COMPOSITIONS AND METHODS FOR INCREASING THE METABOLIC LIFETIME OF DEXTROMETHORPHAN AND RELATED PHARMACODYNAMIC EFFECTS | 15/236,290 | 8/12/2016 |
| IMPLANTABLE POLYMERIC DEVICE FOR SUSTAINED RELEASE OF SUFENTANIL | 15/238,614 | 8/16/2016 |
| COMPOSITIONS AND METHODS COMPRISING BUPROPION OR RELATED COMPOUNDS FOR SUSTAINED DELIVERY OF DEXTROMETHORPHAN | 15/238,182 | 8/16/2016 |
| BISPHOSPHONATES INHIBIT PAIN, BONE LOSS AND INFLAMMATION OF COMPLEX REGIONAL PAIN SYNDROME | 62/378,140 | 8/22/2016 |
| COMPOSITIONS COMPRISING RANK/RANKL ANTAGONISTS AND RELATED COMPOUNDS FOR TREATING PAIN | 15/246,325 | 8/24/2016 |
| COMPOSITIONS AND METHODS FOR INCREASING THE METABOLIC LIFETIME OF DEXTROMETHORPHAN AND RELATED PHARMACODYNAMIC EFFECTS | 15/263,138 | 9/12/2016 |
| COMPOSITIONS COMPRISING RANK/RANKL ANTAGONISTS AND RELATED COMPOUNDS FOR TREATING PAIN | 15/269,799 | 9/19/2016 |
| HYDROXYBUPROPION AND RELATED COMPOUNDS AS MODULATORS OF DRUG PLASMA LEVELS | 15/275,177 | 9/23/2016 |
| COMPOSITIONS AND METHODS FOR INCREASING THE METABOLIC LIFETIME OF DEXTROMETHORPHAN AND RELATED PHARMACODYNAMIC EFFECTS | 15/280,938 | 9/29/2016 |

| | | |
|--|------------|------------|
| OSTEOCLAST INHIBITORS FOR KNEE CONDITIONS | 62/405,838 | 10/7/2016 |
| OSTEOCLAST INHIBITORS FOR KNEE CONDITIONS | 15/335,381 | 10/26/2016 |
| COMPOSITIONS FOR ORAL ADMINISTRATION OF ZOLEDRONIC ACID OR RELATED COMPOUNDS FOR TREATING COMPLEX REGIONAL PAIN SYNDROME | 15/347,696 | 11/9/2016 |
| COMPOSITIONS FOR ORAL ADMINISTRATION OF ZOLEDRONIC ACID OR RELATED COMPOUNDS FOR TREATING COMPLEX REGIONAL PAIN SYNDROME | 15/348,842 | 11/10/2016 |
| COMPOSITIONS FOR ORAL ADMINISTRATION OF ZOLEDRONIC ACID OR RELATED COMPOUNDS FOR TREATING COMPLEX REGIONAL PAIN SYNDROME | 15/348,808 | 11/10/2016 |
| COMPOSITIONS FOR ORAL ADMINISTRATION OF ZOLEDRONIC ACID OR RELATED COMPOUNDS FOR TREATING COMPLEX REGIONAL PAIN SYNDROME | 15/349,926 | 11/11/2016 |
| DOSAGE FORMS FOR ORAL ADMINISTRATION OF ZOLEDRONIC ACID OR RELATED COMPOUNDS FOR TREATING DISEASE | 15/352,461 | 11/15/2016 |
| COMPOSITIONS FOR ORAL ADMINISTRATION OF ZOLEDRONIC ACID OR RELATED COMPOUNDS FOR TREATING COMPLEX REGIONAL PAIN SYNDROME | 15/353,550 | 11/16/2016 |
| COMPOSITIONS FOR ORAL ADMINISTRATION OF ZOLEDRONIC ACID OR RELATED COMPOUNDS FOR TREATING COMPLEX REGIONAL PAIN SYNDROME | 15/354,862 | 11/17/2016 |

| | | |
|--|------------|------------|
| COMPOSITIONS FOR ORAL ADMINISTRATION OF ZOLEDRONIC ACID OR RELATED COMPOUNDS FOR TREATING COMPLEX REGIONAL PAIN SYNDROME | 15/354,908 | 11/17/2016 |
| OSTEOCLAST INHIBITORS FOR KNEE CONDITIONS | 15/356,434 | 11/18/2016 |
| DOSAGE FORMS FOR ORAL ADMINISTRATION OF ZOLEDRONIC ACID OR RELATED COMPOUNDS FOR TREATING DISEASE | 15/357,769 | 11/21/2016 |
| CO-ADMINISTRATION OF STEROIDS AND ZOLEDRONIC ACID TO PREVENT AND TREAT PAIN | 15/357,932 | 11/21/2016 |
| OSTEOCLAST INHIBITORS FOR KNEE CONDITIONS | 15/360,886 | 11/23/2016 |
| OSTEOCLAST INHIBITORS FOR KNEE CONDITIONS | 15/364,117 | 11/29/2016 |
| DOSAGE FORMS FOR ORAL ADMINISTRATION OF ZOLEDRONIC ACID OR RELATED COMPOUNDS FOR TREATING DISEASE | 15/365,748 | 11/30/2016 |
| OSTEOCLAST INHIBITORS FOR KNEE CONDITIONS | 15/367,048 | 12/1/2016 |
| OSTEOCLAST INHIBITORS FOR KNEE CONDITIONS | 15/368,355 | 12/2/2016 |
| OSTEOCLAST INHIBITORS FOR KNEE CONDITIONS | 15/371,052 | 12/6/2016 |
| NERIDRONIC ACID MOLECULAR COMPLEX FOR TREATING COMPLEX REGIONAL PAIN SYNDROME | 62/431,287 | 12/7/2016 |
| COMPOSITIONS FOR ORAL ADMINISTRATION OF ZOLEDRONIC ACID OR RELATED COMPOUNDS FOR TREATING COMPLEX REGIONAL PAIN SYNDROME | 15/377,907 | 12/13/2016 |

| | | |
|--|------------|------------|
| COMPOSITIONS FOR ORAL ADMINISTRATION OF ZOLEDRONIC ACID OR RELATED COMPOUNDS FOR TREATING COMPLEX REGIONAL PAIN SYNDROME | 15/378,939 | 12/14/2016 |
| COMPOSITIONS FOR ORAL ADMINISTRATION OF ZOLEDRONIC ACID OR RELATED COMPOUNDS FOR TREATING COMPLEX REGIONAL PAIN SYNDROME | 15/380,824 | 12/15/2016 |
| CO-ADMINISTRATION OF STEROIDS AND ZOLEDRONIC ACID TO PREVENT AND TREAT PAIN | 15/384,125 | 12/19/2016 |
| OSTEOCLAST INHIBITORS FOR KNEE CONDITIONS | 15/385,415 | 12/20/2016 |
| DOSAGE FORMS FOR ORAL ADMINISTRATION OF ZOLEDRONIC ACID OR RELATED COMPOUNDS FOR TREATING DISEASE | 15/386,858 | 12/21/2016 |
| COMPOSITIONS FOR ORAL ADMINISTRATION OF ZOLEDRONIC ACID OR RELATED COMPOUNDS FOR TREATING PAGET'S DISEASE OF BONE | 15/403,073 | 1/10/2017 |
| COMPOSITIONS FOR ORAL ADMINISTRATION OF ZOLEDRONIC ACID OR RELATED COMPOUNDS FOR TREATING PAGET'S DISEASE OF BONE | 62/445,646 | 1/12/2017 |
| COMPOSITIONS FOR ORAL ADMINISTRATION OF ZOLEDRONIC ACID OR RELATED COMPOUNDS FOR TREATING COMPLEX REGIONAL PAIN SYNDROME | 15/408,783 | 1/18/2017 |
| ADMINISTRATION OF ZOLEDRONIC ACID TO TREAT PAIN ASSOCIATED WITH ANKYLOSING SPONDYLITIS | 15/414,402 | 1/24/2017 |

| | | |
|--|------------|-----------|
| COMPOSITIONS FOR ORAL ADMINISTRATION OF ZOLEDRONIC ACID OR RELATED COMPOUNDS FOR TREATING COMPLEX REGIONAL PAIN SYNDROME | 15/416,995 | 1/26/2017 |
| COMPOSITIONS COMPRISING DASATINIB FOR TREATING COMPLEX REGIONAL PAIN SYNDROME | 15/421,205 | 1/31/2017 |
| COMPOSITIONS FOR ADMINISTRATION OF ZOLEDRONIC ACID OR RELATED COMPOUNDS FOR TREATING LOW BACK PAIN | 15/426,908 | 2/7/2017 |
| DOSAGE FORMS FOR ORAL ADMINISTRATION OF ZOLEDRONIC ACID OR RELATED COMPOUNDS FOR TREATING DISEASE | 15/432,777 | 2/14/2017 |
| OSTEOCLAST INHIBITORS FOR JOINT CONDITIONS | 15/438,513 | 2/21/2017 |
| COMPOSITIONS FOR ORAL ADMINISTRATION OF ZOLEDRONIC ACID OR RELATED COMPOUNDS FOR TREATING COMPLEX REGIONAL PAIN SYNDROME | 15/439,774 | 2/22/2017 |
| COMPOSITIONS FOR ORAL ADMINISTRATION OF ZOLEDRONIC ACID OR RELATED COMPOUNDS FOR TREATING COMPLEX REGIONAL PAIN SYNDROME | 15/446,971 | 3/1/2017 |